ECSP045232A - Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral - Google Patents

Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral

Info

Publication number
ECSP045232A
ECSP045232A EC2004005232A ECSP045232A ECSP045232A EC SP045232 A ECSP045232 A EC SP045232A EC 2004005232 A EC2004005232 A EC 2004005232A EC SP045232 A ECSP045232 A EC SP045232A EC SP045232 A ECSP045232 A EC SP045232A
Authority
EC
Ecuador
Prior art keywords
dosage form
pharmaceutically acceptable
prepare
oral dosage
core
Prior art date
Application number
EC2004005232A
Other languages
English (en)
Inventor
Luigi Martini
Vincenzo Re
Chi Leung Li
Helen Anne Willy
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203298A external-priority patent/GB0203298D0/en
Priority claimed from GB0203297A external-priority patent/GB0203297D0/en
Priority claimed from GBGB0203296.9A external-priority patent/GB0203296D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ECSP045232A publication Critical patent/ECSP045232A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una forma de dosificación oral, que comprende: (i) un núcleo erosionable, núcleo que comprende una base débil farmacéuticamente activa o una sal o solvato de la misma farmacéuticamente aceptable; y (ii) un recubrimiento erosionable rodeando a dicho núcleo, recubrimiento que comprende una o más aberturas que se extienden de modo sustancialmente completo a través de dicho recubrimiento pero que no penetran en dicho núcleo y que comunican el medio de uso con dicho núcleo; en donde la liberación de la base débil farmacéuticamente activa o de una sal o solvato de la misma farmacéuticamente aceptable a partir de la forma de dosificación ocurre sustancialmente por erosión de dicho núcleo erosionable y a través de dicha(s) abertura(s) y a través de la erosión de dicho recubrimiento erosionable en condiciones predeterminadas de pH; un procedimiento para preparar dicha forma de dosificación y el uso de una base débil farmacéuticamente activa para preparar dicha forma de dosificación de aplicación en medicina.
EC2004005232A 2002-02-12 2004-08-12 Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral ECSP045232A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203298A GB0203298D0 (en) 2002-02-12 2002-02-12 Novel composition
GB0203297A GB0203297D0 (en) 2002-02-12 2002-02-12 Novel composition
GBGB0203296.9A GB0203296D0 (en) 2002-02-12 2002-02-12 Novel composition

Publications (1)

Publication Number Publication Date
ECSP045232A true ECSP045232A (es) 2004-09-28

Family

ID=27738830

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005232A ECSP045232A (es) 2002-02-12 2004-08-12 Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral

Country Status (33)

Country Link
EP (1) EP1474114B1 (es)
JP (2) JP2005526031A (es)
KR (2) KR20100086084A (es)
CN (1) CN100444833C (es)
AP (1) AP1736A (es)
AR (1) AR038417A1 (es)
AT (1) ATE455540T1 (es)
AU (1) AU2003245763B2 (es)
BR (1) BRPI0307319B8 (es)
CA (1) CA2475544A1 (es)
CL (1) CL2007003010A1 (es)
CO (1) CO5601025A2 (es)
CY (1) CY1109939T1 (es)
DE (1) DE60331041D1 (es)
DK (1) DK1474114T3 (es)
EA (1) EA008286B1 (es)
EC (1) ECSP045232A (es)
ES (1) ES2336319T3 (es)
IL (1) IL163098A (es)
IS (1) IS2747B (es)
MA (1) MA27689A1 (es)
MX (1) MXPA04007794A (es)
MY (1) MY139719A (es)
NO (1) NO334453B1 (es)
NZ (1) NZ534152A (es)
OA (1) OA12770A (es)
PE (1) PE20030800A1 (es)
PL (1) PL206596B1 (es)
PT (1) PT1474114E (es)
SI (1) SI1474114T1 (es)
TW (1) TWI286079B (es)
UY (1) UY27660A1 (es)
WO (1) WO2003068195A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0120835D0 (en) 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
AU2007211091B8 (en) * 2006-01-27 2013-08-29 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes

Also Published As

Publication number Publication date
OA12770A (en) 2006-07-04
AP1736A (en) 2007-05-02
NO20043633L (no) 2004-10-27
UY27660A1 (es) 2003-09-30
WO2003068195A1 (en) 2003-08-21
MY139719A (en) 2009-10-30
CN100444833C (zh) 2008-12-24
IS2747B (is) 2011-08-15
DE60331041D1 (de) 2010-03-11
EA008286B1 (ru) 2007-04-27
TWI286079B (en) 2007-09-01
KR101048925B1 (ko) 2011-07-12
JP2010159301A (ja) 2010-07-22
BR0307319A (pt) 2005-01-04
BRPI0307319B8 (pt) 2021-05-25
EA200401071A1 (ru) 2004-12-30
NZ534152A (en) 2006-11-30
TW200307567A (en) 2003-12-16
CN1655768A (zh) 2005-08-17
AU2003245763B2 (en) 2008-12-11
IL163098A (en) 2009-05-04
SI1474114T1 (sl) 2010-04-30
PL206596B1 (pl) 2010-08-31
PL371368A1 (en) 2005-06-13
CO5601025A2 (es) 2006-01-31
EP1474114B1 (en) 2010-01-20
PT1474114E (pt) 2010-03-04
CL2007003010A1 (es) 2008-01-25
KR20040084900A (ko) 2004-10-06
NO334453B1 (no) 2014-03-03
AR038417A1 (es) 2005-01-12
ES2336319T3 (es) 2010-04-12
KR20100086084A (ko) 2010-07-29
CA2475544A1 (en) 2003-08-21
IS7383A (is) 2004-08-05
JP2005526031A (ja) 2005-09-02
AU2003245763A1 (en) 2003-09-04
JP5279757B2 (ja) 2013-09-04
MA27689A1 (fr) 2006-01-02
BRPI0307319B1 (pt) 2018-05-02
MXPA04007794A (es) 2004-10-15
PE20030800A1 (es) 2003-10-31
CY1109939T1 (el) 2014-09-10
ATE455540T1 (de) 2010-02-15
DK1474114T3 (da) 2010-04-12
HK1072194A1 (en) 2005-08-19
AP2004003087A0 (en) 2004-09-30
EP1474114A1 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
WO2002011764A3 (en) PHARMACEUTICAL COMPOSITIONS
DE60323482D1 (de) Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
IS6102A (is) Fljótleysanleg skammtaform sem innihalda gelatín úr fiski
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
SE0100901D0 (sv) New composition
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE307593T1 (de) Mit einem tensid co-mikronisiertes progestin, pharmazeutische zusammensetzung dieses enthaltend,verfahren zu deren herstellung sowie verwendung
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
CY1109939T1 (el) Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
UY28461A1 (es) Composición nueva
EA200701409A1 (ru) Новая композиция
ATE425731T1 (de) Pharmazeutische zusammensetzungen eines nichtmagensaftresistenten protonenpumpen-hemmers mit einer carbonat- und bicarbonatsalzkombination
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
CY1116070T1 (el) Σκευασματα οξυκωδονης για μια φορα ημερησιως
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.